Alarming trend of antibiotic resistance in Pseudomonas aeruginosa isolates

Journal of Pure and Applied Microbiology

Volumn 6, Issue 1, 2012, Pages 175-183

  El Zowalaty, Mohamed Ezzat ^a  

^a Zagazig University   (Egypt)

Author keywords

lactamases; Efflux pumps; Multidrug resistance; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; BETA LACTAMASE; CEFIXIME; CEFOPERAZONE; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLAVULANATE POTASSIUM; CLOXACILLIN; DOXYCYCLINE; GENTAMICIN; IMIPENEM; MEROPENEM; NORFLOXACIN; PIPERACILLIN; POLYMYXIN B; STREPTOMYCIN; TICARCILLIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; DRUG EFFICACY; EAR INFECTION; EGYPT; ENZYME ACTIVITY; IN VITRO STUDY; NONHUMAN; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WOUND INFECTION;

PSEUDOMONAS AERUGINOSA;

EID: 84872743305     PISSN: 09737510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Alibert-Franco S, Pradines B, Mahamoud A et al. Efflux mechanism, an attractive target to combat multidrug resistant Plasmodium falciparum and Pseudomonas aeruginosa. Curr Med Chem 2009; 16: 301-17.
2. Al-Jasser AM, Elkhizzi NA. Antimicrobial susceptibility pattern of clinical isolates of Pseudomonas aeruginosa. Saudi Med J 2004; 25: 780-4. (Pubitemid 38877923)
3. Al-Tawfiq JA. Occurrence and antimicrobial resistance pattern of inpatient and outpatient isolates of Pseudomonas aeruginosa in a Saudi Arabian hospital: 1998-2003. Int J Infect Dis 2007; 11: 109-14.
4. Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Chemother 48 Suppl 2001; 1: 5-16.
5. Bell SM, Pham JN, Gatus BJ et al. Isolation of an extended spectrum beta-lactamase producing Pseudomonas aeruginosa from a patient in a Sydney hospital. Pathology 2007; 39: 189-90.
6. Bratu S, Quale J, Cebular S et al. Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York: molecular epidemiology and in vitro activity of polymyxin B. Eur J Clin Microbiol Infect Dis 2005; 24: 196-201. (Pubitemid 40576666)
7. Corona-Nakamura AL, Miranda-Novales MQ, Leanos-Miranda B et al. Epidemiologic Study of Pseudomonas aeruginosa in critical patients and reservoirs. Arch Med Res 2001; 32: 238-42. (Pubitemid 32499536)
8. Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 2007;67:351-68. (Pubitemid 46425550)
9. Drissi M, Ahmed ZB, Dehecq B et al. Antibiotic susceptibility and mechanisms of beta-lactam resistance among clinical strains of Pseudomonas aeruginosa: first report in Algeria. Med Mal Infect 2008;38:187-91.
10. El Kholy A, Baseem H, Hall GS et al. Antimicrobial resistance in Cairo, Egypt 1999-2000: a survey of five hospitals. J Antimicrob Chemother 2003;51:625-30. (Pubitemid 36336156)
11. Gad GF, El-Domany RA, Zaki S, Ashour HM. Characterization of Pseudomonas aeruginosa isolated from clinical and environmental samples in Minia, Egypt: prevalence, antibiogram and resistance mechanisms. J Antimicrob Chemother 2007;60:1010-17. (Pubitemid 47617748)
12. Gailiene G, Pavilonis A, Kareiviene V. The peculiarities of Pseudomonas aeruginosa resistance to antibiotics and prevalence of serogroups. Medicina (Kaunas) 2007;43:36-42.
13. Gales AC, Jones RN, Turnidge J et al. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32 Suppl 2:S146-55. (Pubitemid 32424268)
14. Gencer S, Ak O, Benzonana N et al. Susceptibility patterns and cross resistances of antibiotics against Pseudomonas aeruginosa in a teaching hospital of Turkey. Ann Clin Microbiol Antimicrob 2002; 1: 2.
15. Gonlugur U, Bakici MZ, Ozdemir L et al. Retrospective analysis of antibiotic susceptibility patterns of respiratory isolates of Pseudomonas aeruginosa in a Turkish University Hospital. Ann Clin Microbiol Antimicrob 2003; 2: 5.
16. Hancock RE, Speert DP. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. Drug Resist Updat 2000; 3: 247-55.
17. Hogardt M, Schmoldt S, Gotzfried M et al. Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J Antimicrob Chemother 2004; 54: 1057-61. (Pubitemid 40136741)
18. Huang SS, Labus BJ, Samuel MC et al. Antibiotic resistance patterns of bacterial isolates from blood in San Francisco County, California, 1996-1999. Emerg Infect Dis 2002; 8: 195-201. (Pubitemid 34207664)
19. Japoni A, Alborzi A, Kalani M et al. Susceptibility patterns and cross-resistance of antibiotics against Pseudomonas aeruginosa isolated from burn patients in the South of Iran. Burns 2006;32:343-7.
20. Kaatz GW. Inhibition of bacterial efflux pumps: a new strategy to combat increasing antimicrobial agent resistance. Expert Opin Emerg Drugs 2002;7:223-33. (Pubitemid 35291453)
21. Lambert PA. Mechanisms of antibiotic resistance in Pseudomonas aeruginosa. J R Soc Med 2002;95 Suppl 41:22-26. (Pubitemid 34713187)
22. Landman D, Bratu S, Alam M, Quale. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. J Antimicrob Chemother 2005;55:954-7. (Pubitemid 40883181)
23. Lee YC, Ahn BJ, Jin JS et al. Molecular characterization of Pseudomonas aeruginosa isolates resistant to all antimicrobial agents, but susceptible to colistin, in Daegu, Korea. J Microbiol 2007;45:358-63.
24. Livermore DM, Brown DF. Detection of beta-lactamase-mediated resistance. J Antimicrob Chemother 48 Suppl 2001;1:59-64.
25. Lodise TP, Miller CD, Graves J et al. Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance. Antimicrob Agents Chemother 2007;51:417-22. (Pubitemid 46185255)
26. Marra AR, Bar K, Bearman GM et al. Systemic inflammatory response syndrome in nosocomial bloodstream infections with Pseudomonas aeruginosa and Enterococcus Species: comparison of elderly and nonelderly patients. J Am Geriatr Soc 2006;54:804-8. (Pubitemid 44030203)
27. Mogayzel PJ,Jr, Flume PA. Update in cystic fibrosis 2009. Am J Respir Crit Care Med 2010;181:539-44.
28. Muthu SE, Aberna RA, Mohan V et al. Phenotypes of isolates of Pseudomonas aeruginosa in a diabetes care center. Arch Med Res 2006;37:95-101. (Pubitemid 41727897)
29. Nishino K, Yamaguchi A. Role of histone-like protein H-NS in multidrug resistance of Escherichia coli. J Bacteriol 2004;186:1423-9. (Pubitemid 38248733)
30. Obritsch MD, Fish DN, MacLaren R, Jung R. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy 2005; 25: 1353-64. (Pubitemid 41407633)
31. Ohara M, Kouda S, Onodera M et al. Molecular characterization of imipenem-resistant Pseudomonas aeruginosa in Hiroshima, Japan. Microbiol Immunol 2007;51:271-7. (Pubitemid 46449949)
32. Ohmagari N, Hanna H, Graviss L et al. Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer 2005;104:205-12. (Pubitemid 40847770)
33. Raja NS, Singh NN. Antimicrobial susceptibility pattern of clinical isolates of Pseudomonas aeruginosa in a tertiary care hospital. J Microbiol Immunol Infect 2007;40:45-9. (Pubitemid 47047137)
34. Rhomberg PR, Deshpande LM, Kirby JT, Jones RN. Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006). Diagn Microbiol Infect Dis 2007;59:425-32. (Pubitemid 350184218)
35. Romao CM, Faria YN, Pereira LR, Asensi MD. Susceptibility of clinical isolates of multiresistant Pseudomonas aeruginosa to a hospital disinfectant and molecular typing. Mem Inst Oswaldo Cruz 2005;100:541-8. (Pubitemid 41424082)
36. Saiman L. Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: 'the motion for'. Paediatr Respir Rev 2007; 8: 249-55. (Pubitemid 47440663)
37. Strateva T, Ouzounova-Raykova V, Markova B et al. Problematic clinical isolates of Pseudomonas aeruginosa from the university hospitals in Sofia, Bulgaria: current status of antimicrobial resistance and prevailing resistance mechanisms. J Med Microbiol 2007;56:956-63. (Pubitemid 47047490)
38. Tam VH, Chang KT, LaRocco MT et al. Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2007;58:309-14. (Pubitemid 47017651)
39. Tassios PT, Gennimata V, Spaliara-Kalogeropoulou L et al. Multiresistant Pseudomonas aeruginosa serogroup O:11 outbreak in an intensive care unit. Clin Microbiol Infect 1997;3:621-8. (Pubitemid 28033436)
40. Wang C, Cai P, Chang D, Mi Z. A Pseudomonas aeruginosa isolate producing the GES-5 extended-spectrum beta-lactamase. J Antimicrob Chemother 2006;57:1261-2. (Pubitemid 44644441)
41. Wang J, Zhou JY, Qu TT et al. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Chinese hospitals. Int J Antimicrob Agents 2010; 35: 486-491.
42. Wikler MA, Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing : eighteenth informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA,USA. 2008.
43. Yetkin G, Otlu B, Cicek A et al. Clinical, microbiologic, and epidemiologic characteristics of Pseudomonas aeruginosa infections in a University Hospital, Malatya, Turkey. Am J Infect Control 2006;34:188-192.
44. Zavascki AP, Carvalhaes CG, Picao RC, Gales AC. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther 2010; 8: 71-93.